Tesamorelin Research Guide
GHRH analogue research peptide
Tesamorelin is a stabilized analogue of growth-hormone-releasing hormone (GHRH) developed by Theratechnologies. Originally approved by the FDA in 2010 for HIV-associated lipodystrophy, it remains the most clinically validated GHRH analogue in the research literature, with a documented profile of visceral adipose tissue reduction and IGF-1 elevation through endogenous GH stimulation.
Contents
|
GHRH analogue Mechanism class |
FDA approved HIV lipodystrophy |
Daily SC Dosing route |
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid peptide modified from native human growth-hormone-releasing hormone (GHRH 1-44) by the addition of a trans-3-hexenoyl group at the N-terminus. This modification dramatically extends plasma half-life compared to native GHRH, which is degraded within minutes by dipeptidyl peptidase-4.
Mechanistically, Tesamorelin binds the GHRH receptor on pituitary somatotropes, triggering pulsatile release of endogenous growth hormone. The downstream IGF-1 elevation drives the metabolic and tissue effects observed in research and clinical studies. Because it works through endogenous GH release rather than exogenous GH administration, the response respects natural negative feedback loops and produces a more physiologically patterned GH profile.
Aeternum Labs supplies Tesamorelin as a lyophilized 10 mg vial. Each batch is verified to 99%+ purity by HPLC with mass spectrometry sequence confirmation, LAL endotoxin screening, and a publicly published Certificate of Analysis tied to the lot number.
Mechanism of action
Tesamorelin binds the growth-hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor expressed on pituitary somatotropes. Receptor activation increases intracellular cAMP, which drives the release of stored growth hormone from secretory granules into systemic circulation.
The released growth hormone then exerts both direct and indirect effects. Direct effects include stimulation of lipolysis in adipose tissue and inhibition of glucose uptake in skeletal muscle. Indirect effects, mediated through liver IGF-1 production, include anabolic stimulation of protein synthesis in muscle and connective tissue.
The visceral-adipose-tissue specific reduction observed in Tesamorelin clinical studies appears to be driven by enhanced lipolytic sensitivity of visceral adipocytes to growth hormone, combined with the pulsatile release pattern that endogenous-GH stimulation produces.
Research history
Tesamorelin was developed by Theratechnologies through the 2000s and received FDA approval in 2010 for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Approval was based on two large Phase 3 trials demonstrating significant visceral adipose tissue reduction with manageable side-effect profiles.
Subsequent research has expanded the published literature into non-alcoholic fatty liver disease (now called MASLD), cognitive function in aging, and body composition research outside the HIV indication. The long safety record from the lipodystrophy program provides one of the most extensive human exposure data sets for any GHRH analogue.
Most recently, Tesamorelin has been investigated in MASH (metabolic-associated steatohepatitis) studies, where its visceral-fat-reducing properties are hypothesized to translate into improvements in liver fat content. Published Phase 2 data show reductions in hepatic fat fraction comparable to the visceral fat reductions seen in lipodystrophy research.
Half-life and pharmacokinetics
Tesamorelin has a plasma elimination half-life of approximately 26 minutes after subcutaneous administration. The trans-3-hexenoyl N-terminal modification protects against dipeptidyl peptidase-4 cleavage, extending the half-life from the seconds-to-minutes range of native GHRH to the practical clinical range required for daily administration.
Subcutaneous administration produces a sharp GH spike within thirty to sixty minutes, with the GH pulse decaying over the next two to three hours. IGF-1 elevation builds over days to weeks of continuous administration, reflecting the cumulative effect of repeated GH pulses on hepatic IGF-1 synthesis.
Pharmacokinetic note
Daily subcutaneous administration is required because of the short plasma half-life. The downstream IGF-1 elevation builds over 1-2 weeks of consistent dosing, reaching steady-state by approximately 14 days.
Typical research doses
The clinically approved dose for HIV lipodystrophy is 2 mg administered subcutaneously once daily. This dose is also the most-studied research dose in non-HIV applications including MASLD and body composition research.
Lower doses (1 mg daily) have been studied in dose-finding research and produce smaller but still measurable IGF-1 elevations and visceral fat reductions. Higher doses are not commonly used in published research because the 2 mg dose appears to produce maximum visceral-fat-reduction effects without proportional benefit at higher exposures.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
For Tesamorelin, a 10 mg vial reconstituted with 5 mL of bacteriostatic water yields 2 mg/mL. Each 1 mL volume contains 2 mg, the standard daily research dose, simplifying volume measurement and reducing the chance of dose error.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
Tesamorelin + Ipamorelin (GH and ghrelin axis research)
Ipamorelin is a selective ghrelin receptor agonist that triggers GH release through a different receptor pathway than GHRH analogues. Combined research uses both pathways simultaneously to maximize the endogenous GH pulse without exceeding either receptor’s maximum response.
Tesamorelin + Retatrutide (metabolic and body composition research)
Retatrutide’s triple-receptor incretin activity drives total fat mass reduction through a metabolic mechanism, while Tesamorelin specifically reduces visceral adipose tissue through GH-axis activation. The combination is researched for body composition endpoints where total and visceral fat reductions are both of interest.
Tesamorelin + CJC-1295 No DAC (extended GH-axis research)
CJC-1295 No DAC is a GHRH analogue with similar mechanism but different pharmacokinetic profile. Combined research with Tesamorelin allows comparison of acute (CJC-1295 No DAC) versus sustained-pulse (Tesamorelin) GH-axis activation patterns.
How it compares
Compared to native GHRH: Tesamorelin extends plasma half-life from seconds to approximately 26 minutes through N-terminal modification. This makes daily subcutaneous dosing practical, where native GHRH would require continuous infusion for any meaningful research application.
Compared to CJC-1295 with DAC: CJC-1295 with DAC has a much longer half-life (approximately 7-10 days) due to albumin-binding modification, but produces a sustained GH elevation rather than the pulsatile pattern that Tesamorelin produces. Different research contexts favor different patterns.
Compared to growth hormone secretagogues acting on the ghrelin receptor (e.g., ipamorelin, MK-677): Tesamorelin acts on the GHRH receptor, while ghrelin-receptor agonists act on a different pathway. Both routes drive GH release, and combined research uses both simultaneously to maximize endogenous pulse amplitude.
From the Aeternum library
Tesamorelin (10 mg)
- 99%+ purity verified by HPLC
- Mass spec sequence confirmation
- LAL endotoxin screening
- Full Certificate of Analysis published
- Lyophilized powder, 10 mg
Frequently asked questions
What is the difference between Tesamorelin and exogenous growth hormone?
Tesamorelin stimulates endogenous growth hormone release from the pituitary by activating the GHRH receptor. Exogenous growth hormone administration delivers GH directly into systemic circulation. Tesamorelin produces a pulsatile GH pattern that respects natural negative feedback loops, while exogenous GH produces sustained elevated levels that can override these feedback mechanisms.
Why is daily dosing required?
Tesamorelin has a plasma half-life of approximately 26 minutes. Daily subcutaneous administration is required to produce a consistent GH-pulse pattern, which then drives the cumulative IGF-1 elevation and downstream metabolic effects observed in research.
How does Tesamorelin compare to CJC-1295?
Both are GHRH analogues with extended half-lives compared to native GHRH. Tesamorelin’s modification produces approximately 26-minute plasma half-life with pulsatile GH response. CJC-1295 with DAC modification produces 7-10 day half-life with sustained GH elevation. The choice depends on whether pulsatile or sustained GH-axis activation is preferred for the specific research question.
What dose is used in published research?
The clinically approved and most-studied research dose is 2 mg administered subcutaneously once daily. Lower doses (1 mg daily) have been studied in dose-finding research and produce smaller but measurable effects.
How long does reconstituted Tesamorelin last?
Reconstituted with bacteriostatic water and stored at 36–46°F (2–8°C), Tesamorelin working solution is stable for approximately twenty-eight days. Sealed lyophilized vials at 0°F (−18°C) are stable up to twenty-four months.
References
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. View source
- Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. View source
- Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. View source
- Adrian S, Scherzinger A, Sanyal A, et al. (2018). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults With HIV. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for metabolic research →
Compare
CJC-1295 vs Tesamorelin →
Pair with
CJC-1295 + Ipamorelin guide →
Pair with
Retatrutide research guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.